زولبيديم (zolpidem)

# زولبيديم (zolpidem) ## Overview Zolpidem is a non-benzodiazepine hypnotic (GABA-A receptor agonist) of the imidazopyridine class. It is indicated for the short-term treatment of insomnia characterized by difficulties with sleep initiation. ## Primary Indications - Short-term management of insomnia (difficulty falling asleep). ## Adult Dosing - **Immediate-release (IR):** 5 mg (women/elderly) to 10 mg (men) taken once nightly immediately before bedtime. - **Extended-release (ER):** 6.25 mg (women/elderly) to 12.5 mg (men) taken once nightly immediately before bedtime. - **Maximum Daily Dose:** 10 mg for IR formulations; 12.5 mg for ER formulations. ## Pediatric Dosing - **Not indicated:** Safety and efficacy have not been established in patients under 18 years of age. ## Dose Adjustments - **Hepatic Impairment:** Reduce dose; 5 mg IR or 6.25 mg ER is recommended for patients with mild-to-moderate impairment. Avoid in severe hepatic impairment. - **Elderly (≥65 years):** Start with the lowest possible dose (5 mg IR or 6.25 mg ER) due to increased sensitivity and risk of falls/cognitive impairment. ## Contraindications - Known hypersensitivity to zolpidem. - History of complex sleep behaviors (e.g., sleep-walking, sleep-driving) after taking zolpidem. - Patients with severe respiratory depression or myasthenia gravis (relative). ## Adverse Effects - **Common:** Drowsiness, dizziness, diarrhea, headache, drugged feeling. - **Serious:** Complex sleep behaviors (sleep-walking, eating, or driving while not fully awake), severe allergic reactions (angioedema/anaphylaxis), depression, and anterograde amnesia. ## Key Drug Interactions - **CNS Depressants:** Potentiation of sedation (e.g., alcohol, opioids, benzodiazepines, antipsychotics). - **CYP3A4 Inhibitors:** (e.g., ketoconazole, ritonavir) May significantly increase plasma levels of zolpidem; avoid concomitant use or monitor closely. - **CYP3A4 Inducers:** (e.g., rifampin) May decrease efficacy. ## Monitoring - Monitor for next-day impairment, particularly with driving. - Assess for signs of physical/psychological dependence. - Observe for development of complex sleep behaviors. - Evaluate treatment efficacy after 7–10 days; if insomnia persists, consider underlying comorbidities. ## Clinical Pearls - **Administration:** Must be taken immediately before retiring with at least 7–8 hours of remaining sleep time. - **Onset:** Food significantly slows absorption; for fastest onset, take on an empty stomach. - **Tapering:** Upon discontinuation, consider a gradual dose reduction to avoid withdrawal symptoms or rebound insomnia. - **Sublingual/Oral Spray:** Various formulations (e.g., Edluar, Intermezzo) exist for middle-of-the-night awakening; these require at least 4 hours of remaining sleep time before rising. *** **Educational Disclaimer:** This information is for educational purposes only. Drug prescribing information, including specific dosing and local protocols, must be verified against current institutional guidelines, local formularies, and official product monographs before clinical use. Always consult a healthcare professional before initiating or adjusting therapy.